Valuation : Genix Pharmaceuticals Corporation

Market Cap 1.22M 883K 760K 720K 653K 84.32M 1.23M 8.55M 3.29M 42.9M 3.31M 3.24M 136M P/E 2024
-40.5x
P/E 2025 -5.33x
Enterprise Value 2.22M 1.6M 1.38M 1.31M 1.19M 153M 2.24M 15.53M 5.97M 77.91M 6.02M 5.89M 246M EV / Sales 2024
929,496,174x
EV / Sales 2025 -
Free-Float
53.08%
Yield 2024 *
-
Yield 2025 -
1 month+33.33%
3 months+33.33%
Current year-20.00%
1 month 0.02
Extreme 0.02
0.02
Current year 0.02
Extreme 0.015
0.02
1 year 0.02
Extreme 0.015
0.04
3 years 0.02
Extreme 0.015
0.09
5 years 0.02
Extreme 0.015
0.19
10 years 0.01
Extreme 0.01
0.3
Manager TitleAgeSince
Chief Executive Officer 57 03/08/2018
Director of Finance/CFO - 04/05/2026
President - 21/05/2021
Director TitleAgeSince
Director/Board Member 57 03/08/2018
Director/Board Member 76 11/03/2019
Director/Board Member 44 05/09/2019
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/25 A Option

Chairman

1,000,000 1.6885%
9/9/25 A Option

Chairman

1,000,000 1.6885%
9/9/25 A Option

Chief Executive Officer

1,000,000 1.6885%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-33.33%-60.00% 883K
-1.13%-3.11%+13.82%+60.17% 46.21B
-1.10%-4.43%+32.27%+105.76% 38.78B
+0.12%-0.08%+7.12%+73.98% 11.68B
-0.53%-1.37%-13.25%+11.19% 11.55B
-0.38%-2.26%+18.18%+142.99% 9.14B
+0.32%-2.26%+23.08%+35.61% 7.3B
+0.17%-0.74%+13.44%+180.68% 7.15B
-0.09%-4.22%+32.90%-19.94% 7.1B
-3.13%-4.30%-44.88%+12.88% 4.97B
Average -0.58%-2.33%+4.94%+54.33% 14.39B
Weighted average by Cap. -0.81%-3.27%+15.72%+74.06%

Financials

2024 2025
Net sales 0 0 0 0 0 0.28 0 0.03 0.01 0.14 0.01 0.01 0.45 -
Net income -73.2K -52.76K -45.46K -43.04K -39.02K -5.04M -73.57K -511K -197K -2.56M -198K -194K -8.1M -335K -242K -208K -197K -179K -23.07M -337K -2.34M -900K -11.74M -907K -887K -37.09M
Net Debt 804K 580K 499K 473K 429K 55.38M 808K 5.62M 2.16M 28.18M 2.18M 2.13M 89.03M 999K 720K 621K 588K 533K 68.82M 1M 6.98M 2.68M 35.01M 2.71M 2.65M 111M
Logo Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation is a Canadian ophthalmic drugs company. The Company is a formulator, manufacturer, licensor and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its operations consist primarily of the research, development, manufacture, in-licensing and sales of novel and healthcare products, focusing on proprietary over the counter (OTC) nutraceuticals and generic pharmaceuticals. The Company has been marketing and selling other nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels and spirulina powder. Its products include Ketorolac 0.5% Eye Drops, Timolol 0.5% Eye Drops, Diclofenac 0.1% Eye Drops, Moxifloxacin Hydrochloride 0.5% Eye Drops, Prednisolone Acetate 1% Eye Drops, Olopatadine 0.1% Eye Drops, and others.
Employees
4,000
  1. Stock Market
  2. Stocks
  3. GENX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!